InflaRx (NASDAQ:IFRX – Get Free Report) is expected to be releasing its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect InflaRx to announce earnings of ($0.08) per share and revenue of $0.0060 million for the quarter. Interested persons can check the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Thursday, August 6, 2026 at 9:30 AM ET.
InflaRx (NASDAQ:IFRX – Get Free Report) last posted its quarterly earnings data on Wednesday, May 6th. The company reported ($0.09) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.08. On average, analysts expect InflaRx to post $-0 EPS for the current fiscal year and $-0 EPS for the next fiscal year.
InflaRx Price Performance
Shares of NASDAQ IFRX opened at $1.78 on Wednesday. InflaRx has a 1 year low of $0.74 and a 1 year high of $2.95. The firm has a 50-day simple moving average of $1.93 and a two-hundred day simple moving average of $1.52. The company has a market cap of $128.68 million, a P/E ratio of -2.51 and a beta of 2.48.
Institutional Inflows and Outflows
Analysts Set New Price Targets
IFRX has been the topic of several recent analyst reports. HC Wainwright increased their price target on InflaRx from $6.00 to $8.00 and gave the stock a “buy” rating in a report on Monday, May 11th. Wall Street Zen upgraded InflaRx from a “sell” rating to a “hold” rating in a report on Saturday, May 9th. Cantor Fitzgerald upped their price objective on InflaRx from $2.00 to $4.00 and gave the company an “overweight” rating in a research report on Monday, May 11th. Weiss Ratings reiterated a “sell (d-)” rating on shares of InflaRx in a research note on Wednesday, June 24th. Finally, Guggenheim reiterated a “buy” rating and issued a $14.00 target price on shares of InflaRx in a research note on Tuesday, April 21st. Two analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $7.00.
Check Out Our Latest Stock Report on IFRX
InflaRx Company Profile
InflaRx N.V. is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies targeting the complement system, with an emphasis on the complement‐1a (C5a) pathway. The company’s lead product candidate, vilobelimab (IFX‐1), is a monoclonal antibody designed to selectively inhibit C5a, a potent pro‐inflammatory peptide implicated in a range of autoimmune and inflammatory diseases. InflaRx seeks to address high‐unmet medical needs by advancing treatments for conditions such as hidradenitis suppurativa, pyoderma gangrenosum and other rare and severe inflammatory disorders.
Vilobelimab has been evaluated in multiple Phase II trials, demonstrating proof of concept in reducing key inflammatory markers and improving clinical outcomes.
Read More
- Five stocks we like better than InflaRx
- System Upgrade: First Internet Bancorp Options Surge
- AI Security Breaches Raise New Risks for Microsoft and Amazon’s Agent Push
- The AI Chip Blockade Is Creating a Shadow Market
- Grab Holdings Stock Forms Bottom After Strong Beat-and-Raise Quarter
Receive News & Ratings for InflaRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InflaRx and related companies with MarketBeat.com's FREE daily email newsletter.
